Early Disease-Modifying Treatments for Presymptomatic Multiple Sclerosis.
Zeydan B, Azevedo CJ, Makhani N, Cohen M, Tutuncu M, Thouvenot E, Siva A, Okuda DT, Kantarci OH, Lebrun-Frenay C.
Zeydan B, et al. Among authors: cohen m.
CNS Drugs. 2024 Sep 16. doi: 10.1007/s40263-024-01117-9. Online ahead of print.
CNS Drugs. 2024.
PMID: 39285136
Review.